About 3 Trademarks found that are owned by Hdt Bio Corp

Nanoparticle formulations as components of RNA-based vaccines, namely, RNA drug delivery agents consisting of a biological compound in the form of nanoparticles that facilitate the delivery of RNA to biological cells

Nanoparticle formulations as components of nucleic acid-based vaccines, medicines, and pharmaceutical preparations, namely, nucleic acid drug delivery agents comprising cationic nanoparticle compositions that complex with one or more nucleic acids for the purpose of delivering such nucleic acid to biological cells for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoemulsion compositions as components of nucleic acid-based vaccines, medicines, and pharmaceutical preparations, namely, nucleic acid drug delivery agents in the nature of compounds combining liquid oils, lipids, and surfactants to form nanoparticles to facilitate the delivery of nucleic acids to biological cells, for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Therapeutic preparations in the nature of vaccines as drug delivery agents consisting of nucleic acid, protein or small-molecule compounds for medicines that facilitate the delivery of a wide range of pharmaceuticals delivered via intramuscular injections, intravenous injections, inhalation, transdermal, intradermal, or intranasal methods, for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoparticles and nanoparticle formulations as components of immunotherapeutics, namely, pharmaceutical preparations in the nature of vaccines and nucleic acid, protein or small-molecule medicines for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoparticles and nanoparticle formulations in the nature of active pharmaceutical ingredient drug delivery agents consisting of compositions in the nature of cationic nanoparticles that facilitate the delivery of medical, biological, pharmaceutical, and therapeutic preparations to biological cells for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoparticles and nanoparticle formulations in the nature of compositions for use as drug delivery agents sold as an integral component of pharmaceutical preparations; Nanoparticles and nanoparticle formulations in the nature of active pharmaceutical ingredients for use as drug delivery agents consisting of a biological composition in the form of nanoparticles sold as an integral component of pharmaceutical preparations for intracellular delivery of nucleic acid to biological cells for the treatment and prevention of a wide variety of diseases, namely, cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases, all for pharmaceutical or medical purposes; Pharmaceutical preparations, namely, lipid-enabled drug delivery systems for nucleic acid, protein or small-molecule medicines comprising small interfering RNA, messenger RNA, antisense, microRNA, DNA, cDNA oligotherapeutic, protein therapeutic agents, and small molecules that facilitate the delivery of pharmaceutical preparations to biological cells to enable the targeting of any gene in the human genome to modulate immune response, sold to pharmaceutical companies for use as an integral component for use in the further manufacture of pharmaceutical preparations for the treatment and prevention of a wide variety of diseases, namely, cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Pharmaceutical preparations for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Pharmaceutical preparations, namely, nucleic acid-based delivery agents comprised of nanoparticle carriers and polymers for the delivery of nucleic acid to human cells; Drug carriers for medical use, namely, drug delivery agents consisting of cationic nanoparticles as compositions that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents consisting of emulsions as compositions that facilitate delivery of a wide range of pharmaceuticals

Nanoparticle formulations as components of RNA-based vaccines, namely, RNA drug delivery agents consisting of biologically active compositions in the form of cationic nanoparticles that facilitate the delivery of RNA to biological cells; Nanoparticle formulations as components of RNA-based vaccines, namely, RNA drug delivery agents consisting of cationic nanoparticle emulsions that facilitate the delivery of RNA to biological cells; Drug delivery agents consisting of emulsions that facilitate delivery of RNA-based vaccines, namely delivery of RNA to biological cells for the prevention of infectious diseases